1312309-62-8 Usage
Description
Mes-PEG2-acid t-butyl ester is a PEG (polyethylene glycol) linker that features a mesyl group and a t-butyl protecting group. The mesyl group serves as an effective leaving group for nucleophilic substitution reactions, while the t-butyl group acts as an acid-labile protecting group. Once the t-butyl group is removed, the resulting carboxylic acid can readily react with primary amines. The hydrophilic PEG linker enhances the compound's water solubility in aqueous environments.
Uses
Used in Pharmaceutical Industry:
Mes-PEG2-acid t-butyl ester is used as a protecting group for carboxylic acids in the pharmaceutical industry. Its acid-labile nature allows for controlled release of the carboxylic acid under specific conditions, which can be beneficial in drug design and synthesis.
Used in Chemical Synthesis:
In the field of chemical synthesis, Mes-PEG2-acid t-butyl ester is used as an intermediate for the synthesis of various compounds. The PEG linker can be utilized to improve the solubility and stability of the target molecules, while the mesyl and t-butyl groups provide opportunities for further functionalization and modification.
Used in Bioconjugation:
Mes-PEG2-acid t-butyl ester is used as a bioconjugation agent for attaching biomolecules, such as proteins or peptides, to other molecules or surfaces. The PEG linker can help to reduce aggregation and increase solubility, while the carboxylic acid can be used to form stable covalent bonds with primary amines on the target biomolecule.
Used in Drug Delivery Systems:
In drug delivery systems, Mes-PEG2-acid t-butyl ester can be employed as a component of prodrugs or drug conjugates. The acid-labile t-butyl group allows for the controlled release of the active drug in response to specific environmental conditions, such as changes in pH or the presence of certain enzymes. This can improve the drug's bioavailability and reduce side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1312309-62-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,2,3,0 and 9 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1312309-62:
(9*1)+(8*3)+(7*1)+(6*2)+(5*3)+(4*0)+(3*9)+(2*6)+(1*2)=108
108 % 10 = 8
So 1312309-62-8 is a valid CAS Registry Number.
1312309-62-8Relevant articles and documents
NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG
-
, (2021/05/14)
PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT
MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
-
Paragraph 00398-00401, (2019/01/06)
The present disclosure relates to bifunctional compounds, which find utility as modulators of c-Met and/or p38 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
